Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report

3rd March 2017 Uncategorised 0

Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report
esagonowsky
Fri, 03/03/2017 – 10:57




More: Celgene, BMS, Novartis expected to top 2022 orphan drug market worth 9B: report
Source: fierce